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Melanoma is known to be highly resistant to chemotherapy.  Treatment with high 
dose IL-2 has shown significant clinical benefit in a minority of metastatic melanoma 
patients and has lead to long term survival in a few cases. However, this treatment is 
associated with excessive multiorgan toxicities, which severely limits its use.  We 
hypothesize that one mechanism of effective IL-2 therapy is through the direct 
upregulation of IL-24 production in melanoma tumors and subsequent IL-24 mediated 
tumor growth suppression. 
Five melanoma cell lines were treated with high dose recombinant hIL-2 at 
1000U/ml.  Three of the cell lines (A375, WM1341, WM793) showed statistically 
significant increases in their levels of IL-24 protein when measured by Western blotting, 
while the remaining two lines (WM35, MeWo) remained negative for IL-24 message and 
protein.  This increase in IL-24 was abolished by either preincubating with an anti-IL-2 
antibody or by blocking the IL-2 receptor directly with antibodies against the receptor 
chains.  We also demonstrated by ELISA that these three cell lines secrete IL-24 protein 
 vi
in higher amounts when stimulated with IL-2 than do untreated cells.  These cells were 
found to contain IL-2R beta and gamma message by RT-PCR and also expressed higher 
levels of IL-24 when treated with IL-15, which shares the IL-2R beta chain.  Thus we 
propose that IL-2 is signaling through IL-2R beta on some melanoma cells to upregulate 
IL-24 protein expression.  To address the biological function of IL-2 in melanoma cells, 
five cell lines were treated with IL-2 and cell viability determined.  Cell growth was 
found to be significantly decreased by day 4 in the IL-24 positive cell lines while no 
effect on growth was seen in WM35 or MeWo.  Incubating the cells with anti-IL-24 
antibody or transfecting with IL-24 siRNA effectively negated the growth suppression 
seen with IL-2.  These data support our hypothesis that in addition to its 
immunotherapeutic effects, IL-2 also acts directly on some melanoma tumors and that the 
IL-24 and IL-2R beta status of a tumor may be useful in predicting patient response to 
high dose IL-2. 
 
 
 vii
Table of Contents 
 
i. Approval 
ii. Title 
iii. Dedication 
iv. Acknowledgements 
v. Abstract 
x. List of Illustrations 
xii. List of Tables 
xiii. Abbreviations 
 
Introduction 
 Skin Cancer and Melanoma ………………………………………...…… 1 
 Melanoma and Immunity ……………………………………...……… 5 
 Interleukin-2 and the IL-2 Receptor Complex     …………………………. 5 
 High Dose Interleukin-2 (IL-2) as an Immunotherapy for  
Metastatic Melanoma …………………………………………...… 8 
 Interleukin-24/melanoma differentiation associated gene-7 ………...…… 9 
 Preliminary data and rationale for hypothesis     …………………...……... 13 
Materials and Methods 
Cell lines and cell culture     ………………………………………………. 15 
Charcoal stripped fetal bovine serum    ………………………...…………. 15 
Reagents   ………………………………………………………………….. 16 
 viii
Whole cell extracts and Western blotting analysis ……………...…..….. 16 
Detection of secreted IL-24 protein …………………………………….. 17 
RNA isolation   ……………………………………………………………. 18 
Real Time Quantitative – RT-PCR Probe based assay    ………………….  18 
Growth suppression assay    ………………………………………………. 21 
siRNA assay ……………………………………………………………... 23 
Statistical analysis    ……………………………………………………….. 23 
Results 
IL-24 message is present in some melanoma cells ……………………... 24 
Basal IL-24 levels in melanoma cells are affected by serum components ... 27 
IL-2 upregulates IL-24 protein production and secretion in 3/5  
melanoma cell lines  ……………………………………………... 29  
Melanoma cells have IL-2R mRNA ……………………………………... 35 
 IL-15 upregulates IL-24 expression in melanoma cell lines ……………... 39 
IL-2 causes growth suppression in some melanoma cells    ………………. 41 
IL-2 mediated growth suppression is dependent on IL-24  ……………….. 42 
IL-15 causes growth suppression in A375 cells  ………………………….. 49 
Serum levels of IL-24 in high dose IL-2 patients    ……………………….. 51 
Discussion 
IL-2 upregulates IL-24 protein expression leading to growth  
suppression in melanoma cells    ………………………………….. 53 
Additional support for IL-24 as a predictive marker for response to IL-2 ... 61 
 
 ix
IL-2Rβ or IL-15Rα coexistence with IL-24 as a predictive marker for  
response to IL-2 therapy………………………………………….... 63 
Support for IL-15 as therapy for metastatic melanoma  …………….…….  64 
 Mechanism of IL-2 dependent IL-24 Upregulation in Melanoma  
Cell Lines …….……………………………………………………  65 
Conclusions …………………………………………………………….. 66 
 Reference List   …………………………………………………………… 68 
Vita ………………………………………………………….………….  100 
 x
List of Illustrations 
 
1. Figure 1. Increased incidence of melanoma in individuals  3 
>45 years of age. 
2. Figure 2. IL-2 receptor signaling 7 
3. Figure 3. IL-24 associated pathways in cancer cell apoptosis 12 
4. Figure 4. Some melanoma cell lines have message for IL-24 26 
5. Figure 5. Charcoal stripped FBS media decreases background 28 
 levels of IL-24 
6. Figure 6. High dose IL-2 upregulates IL-24 expression in  32 
 some melanoma cells 
7. Figure 7. IL-24 is secreted by some melanoma cells 33 
8. Figure 8. IL-2 upregulation of IL-24 can be neutralized with 34 
 anti-IL-2 antibody 
9. Figure 9. IL-2Rβ and IL-2Rγ chain mRNA is present in  37 
 melanoma cell lines 
10. Figure 10. IL-2 mediated IL-24 production is abolished by  38 
 blocking the IL-2R 
11. Figure 11. IL-15 upregulates IL-24 expression in some melanoma 40 
 cells 
12. Figure 12. Effects of IL-2 on melanoma cell growth by Trypan 44-47 
 blue assay 
13. Figure 13. IL-24 siRNA effectively knocks down IL-24 mRNA 48 
 in melanoma cell lines 
 xi
14. Figure 14. IL-15 causes growth suppression in A375 cells by 50  
 day 4 
15. Figure 15. Proposed novel mechanism for IL-2 direct effects on  55 
 melanoma: IL-24 dependent IL-2 mediated growth suppression in  
 melanoma cells 
 xii
 
List of Tables 
 
1. Table 1 – Simplified AJCC 2009 Melanoma Staging and Classification  4 
2. Table 2 – IL-24 and IL-2R chain PCR primers and efficiency  22 
3. Table 3 – Human melanoma cell line descriptions    25 
 xiii
Abbreviations 
ADCC Antibody dependent cell mediated cytotoxicity 
BSA Bovine Serum Albumin 
CSFBS Charcoal stripped fetal bovine serum 
ELISA Enzyme-linked immunosorbent assay 
FACS Fluoresence activated cell sorting 
FBS Fetal Bovine Serum 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRP Horse Radish Peroxidase 
Ig Immunoglobulin 
IL-x Interleukin-x 
IL-2R Interleukin-2 receptor 
LAK Lymphokine activated killer 
LPS Lipopolysaccharide 
mRNA Messenger ribonucleic acid 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
PBMC Peripheral blood mononuclear cells 
PBS Phosphate Buffered Saline 
PHA Phytohemagglutinin 
RPMI Roswell Park Memorial Institute medium 
RT-PCR Reverse transcriptase polymerase chain reaction 
SDS-PAGE Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
siRNA Short-interfering RNA 
 1
Introduction 
 
Skin Cancer and Melanoma 
Skin cancer is the most common type of all cancers, and melanoma is its deadliest 
form.  Although melanoma accounts for less than 5 percent of total skin cancers, it caused 
about 75 percent of all skin cancer deaths last year.  While the incidence of many other 
prevalent cancers has decreased in recent years, the incidence of malignant melanoma is 
steadily rising (Figure 1) [1, 2].  The number of new melanoma cases each year is increasing 
faster than many other cancers in the United States, and in Australia new cases of melanoma 
exceeded new cases of lung cancer for the first time in 2008.  Although it receives little 
attention, melanoma is a very serious cancer problem.  There were an estimated 68,720 new 
cases of melanoma (39,080 men and 29,640 women) and more than 8,650 melanoma deaths 
in the United States in 2009 [3] (NCI SEER Cancer Statistics Review, 2009).   According to 
the American Cancer Society, the mortality rate for melanoma has increased by close to 50 
percent since the early 1970s, and while surgical resection can be curative in the very early 
stages of disease, melanoma demonstrates extremely aggressive growth characteristics.  The 
prognosis for patients with metastatic melanoma remains extremely poor.  Median survival 
for stage III melanoma patients is around 24 months.  Stage IV patient survival ranges from 6 
to 8 months from the time of diagnosis, with 5-year survival rates of less than 4 percent [4, 
5].  Because melanoma can strike early in life, it ranks among the top 5 malignancies in 
terms of years of potential life lost.  Between 2002-2006, the median age at diagnosis for 
melanoma was 59 years of age, and greater than 40 percent of the cases diagnosed were in 
patients younger than 55.  Melanoma is the most commonly occurring cancer in women aged 
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25-29 years, and it is second only to breast cancer in women aged 30-34 years [6].  Median 
age at death for melanoma between 2002-2006 was 68 years of age.   
Cutaneous melanomas develop from melanocytes, the cells responsible for generating 
melanin in the skin.  Melanocytes originate from multipotent neural crest cells, which give 
rise to numerous types of cells including neurons and glial cells, among others [7, 8].  During 
development, melanocyte precursors migrate from the neural crest to several locations within 
the body including the basal layer of the skin, hair, inner ear, uveal tract in the eye, and 
leptomeninges in the brain [9].  Any of these locations can become the site of a primary 
tumor.  When melanoma metastasizes, the most common site is a lymph node closest to the 
primary tumor.  Other common sites of metastasis include the skin, lungs, liver, brain, and 
bone.  In patients with Stage I and II melanoma (local disease), significant beneficial 
prognostic factors include female sex, age >65 years, lesions on the extremities, tumor 
thickness of <0.1mm, and lack of ulceration.  The most recent American Joint Committee on 
Cancer findings add mitotic rate (defined histologically as the number of mitoses/mm2) as a 
prognostic factor (American Joint Committee on Cancer: AJCC Cancer Staging Manual, 
Seventh Edition;[10]).  In Stage III disease (regional metastasis), smaller tumor burden and 
fewer involved lymph nodes were also significant beneficial factors. 
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Figure 1.  Increased incidence of melanoma in individuals >45 years of age.  Comparison 
of three-year melanoma incidence between 1994 – 1996 and 2004 – 2006 grouped by gender.  
SEER Cancer Statistics Review 1975 – 2006, National Cancer Institute, 2008.  Downloaded 
04/2010 from  
 http://seer.cancer.gov/csr/1975_2007/browse_csr.php?section=16&page=sect_16_zfig.03.html  
 4
 
 
 
 
Table 1. Simplified AJCC 2009 Melanoma Staging and Classification 
 
 
I Primary 1.0 mm or less with or without ulceration 
and with or without mitoses ≥1/mm2, or primary 1.01 
- 2.0 mm without ulceration, no lymph node or 
distant metastases 
II Primary 1.01 - 2.0 mm with ulceration, or primary > 
2.01 mm with or without ulceration, no lymph node 
or distant metastases 
III Lymph node metastasis, or in-transit 
metastases/satellites, no distant metastases 
IV Distant metastases 
 
Included with permission to reprint data from Journal of Clinical Oncology (10), License Number 
2416810139111. 
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Melanoma and Immunity 
Melanoma is notoriously resistant to both radiation therapy and cytotoxic 
chemotherapies. Treatment modalities for metastatic melanoma have included surgery, 
radiotherapy, chemotherapy, biologic therapy, hyperthermia limb perfusion, and intralesional 
immunotherapy.  Treatment with chemotherapy, either alone or in combination with other 
chemotherapies, has resulted largely in only partial or nondurable responses in metastatic 
disease [11].  Throughout the course of treating patients, clinicians observed some interesting 
characteristics of the disease including spontaneous regression of primary lesions [12, 13] as 
well as disseminated disease, the presence of T cell infiltrates in early lesions, and the 
existence of a shared melanoma differentiation antigen in melanoma and vitiligo, an 
autoimmune skin disorder [14-16].  In fact, the presence of de novo vitiligo in patients with 
melanoma correlated with a better prognosis and response to immunotherapeutic tumor 
treatment; this was also true if patients had other coexisting autoimmune states such as 
autoimmune thyroid dysfunction [17-20].  This clinically evident relationship between the 
natural history of melanoma and immunity led to the suggestion that combining traditional 
chemotherapy with cytokine immunotherapy might yield cumulative immune and direct 
antitumor effects.   
 
Interleukin-2 and the IL-2 receptor complex 
 Cytokines are protein molecules that are involved in regulating the immune response.  
Interleukin-2 was originally called T-cell growth factor based on its capacity to promote 
long-term proliferation of T cells grown in culture [21].  IL-2 is a member of a family of 
cytokines that includes IL-4, IL-7, IL-9, IL-15, and IL-21.  It mediates its effects by signaling 
 6
through the IL-2 receptor complex (Figure 2).  This complex consists of three chains – the 
IL-2Rα chain (CD25) which is specific for IL-2, the IL-2Rβ chain (CD122), and the common 
γ chain (CD132, γc), which is shared by all members of this family of cytokines.  IL-2Rα 
serves to stabilize the interaction between IL-2 and its receptor but is not involved in signal 
transduction.  All three chains combine to form a high affinity receptor complex, while IL-
2Rβ and IL-2Rγ together form an intermediate affinity receptor.  Binding of IL-2 to its 
receptor activates the Ras/MAPK, JAK/Stat, and PI 3-kinase/Akt signaling pathways.  IL-2 is 
typically produced by the body during an immune response to foreign molecules or microbes 
[22, 23].  Foreign antigens bind to T cell receptors triggering the secretion of IL-2 and the 
expression of IL-2 receptor.  IL-2 interaction with its receptor stimulates growth, 
differentiation and survival of antigen specific cytotoxic T cells by activating expression of 
specific genes [24, 25].  Therefore, IL-2 is essential for the development of T cell 
immunologic memory.   IL-2 is also important during the development of T cells in the 
thymus; it is involved in the maturation of a subset of T cells called regulatory T cells or T-
regs [26, 27].  After leaving the thymus, T-regs prevent other T cells from recognizing and 
responding to self antigens and leading to an autoimmune state.  T-regs accomplish this by 
preventing other T cells from producing IL-2.  Consequently, IL-2 is required to discriminate 
between self and non-self. 
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Figure 2.  IL-2 receptor signaling.  A. The high affinity IL-2 receptor is made up of three subunits - α, β, and 
γ.  B. Binding of IL-2 to its receptor leads to signal transduction via Ras/MAPK, JAK/Stat and PI 3-kinase/Akt.  
Malek et al. Nature Reviews Immunology, 4, 665-674, Sept. 2004.  Included with permission to reprint from 
Nature Publishing Group, License Number 2416781462303. 
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High Dose IL-2 as Immunotherapy for Metastatic Melanoma  
The most promising adjuvant immunotherapy results in metastatic melanoma patients 
thus far have been observed with high dose bolus recombinant human IL-2 treatment, which 
has been shown to have significant clinical benefits and produce long term survival in a 
minority of patients [28-32].  IL-2 is a major regulator of the immune system, and is 
therefore a good contender to stimulate the immune system against cancer.  It has also been 
shown to be effect in some patients with renal cell carcinoma [33-35].  Objective responses 
have been observed in 15% to 20% of melanoma patients, with 6% to 8% of patients 
achieving complete durable responses [36, 37].  Approximately 60% of patients who attain 
complete remission survive for more than 10 years.  High dose IL-2 therapy is currently 
being utilized here at M. D. Anderson Cancer Center both alone and in combination with 
various chemotherapeutic regiments to treat patients with advanced metastatic disease.  In 
initial trials, high dose IL-2 was given intravenously at 600,000 to 720,000 IU/kg every eight 
hours on days 1 to 5 and 15 to 19 with a maximum of 28 doses per course [38, 39].  IL-2 
antitumor activity is thought to be mediated by activation of natural killer cells (NK) to 
lymphokine activated killer cells (LAK) [40-42], in essence enhancing the patient’s immune 
system activity against melanoma.   
However, high dose IL-2 therapy is associated with capillary leak syndrome (also 
commonly called vascular leak syndrome) resulting in severe vascular hypotension and 
extensive multiorgan toxicity, including renal, hepatic, and cardiac [43-47].  It also causes 
arrhythmias and fluid accumulation in the lungs.  These highly toxic side effects severely 
limit its use to patients with healthier organ function and performance status, and thus it 
remains an obstacle to widespread treatment with IL-2.  Only 6-8 % of patients benefit from 
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this treatment and we cannot predict who they are prior to applying a costly and toxic 
therapy.  In addition, hospitalization is required for the duration of treatment, and because of 
the specialized monitoring and support services necessary to administer high dose IL-2 
therapy this treatment is only offered at a limited number of centers.  As of yet, there is no 
reliable marker to identify the melanoma patients who are most likely to respond positively 
to IL-2 therapy.  Identification of such a marker is essential in order to effectively treat these 
patients. 
 
Interleukin-24/melanoma differentiation associated gene-7   
IL-24, initially called melanoma differentiation associated gene-7 (mda-7), is a 
unique multifunctional cytokine belonging to the IL-10 family [48, 49]  The mda-7 gene was 
identified by subtraction hybridization from a melanoma cell line that was induced to 
differentiate with IFN-β and then stabilized by mezerin [50].  IL-24 was initially thought to 
be a transcription factor because it appeared to be localized in the nucleus [51]. However 
since sequence analysis showed a limited homology to IL-10, and IL-24 functions in an 
immune regulatory loop by stimulating monocyte production of a pro-Th-1 cytokine cascade 
(49), IL-24 was ultimately classified as a Th1 cytokine.  IL-24 receptors were shown to 
consist of the class II heterodimeric receptors of IL-22R1/IL-20R2 and IL-20R1/IL-20R2 
[52].  These receptors have been shown to be expressed primarily in the skin where they are 
present on keratinocytes [53, 54], but can also be found on endothelial cells, lung, testis, 
ovarian cells, as well as some cancer cells including melanoma [55].  In normal cells, 
endogenous IL-24 expression is limited to immune cells, including monocytes and stimulated 
T-cells, and skin cells including keratinocytes and melanocytes [48, 56-59].  Our laboratory 
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has shown that IL-24 protein is expressed by nevi and primary melanoma tumors.  This 
protein expression is subsequently lost during melanoma tumor invasion and progression and 
is often undetectable in advanced metastatic disease [60-62].  IL-24 has also been shown to 
cause growth suppression and apoptosis specifically in tumor cells both in vitro and in vivo, 
including lung, pancreatic, and breast cancer cells, while demonstrating no apparent toxicity 
to normal cells [63-65] (Figure 3).  Data from our laboratory further demonstrates the 
cytotoxicity of IL-24 to human melanoma cell lines.  These data are all consistent with the 
tumor suppressor functions attributed to IL-24 [66].  A replication incompetent adenovirus 
expressing the mda-7 gene construct (Ad.mda-7; INGN 241) has been used in many studies 
to further elucidate the biological effects of IL-24.  IL-24 has been observed in vitro and in 
vivo to possess certain anti-angiogenic properties [67, 68].  Human lung tumors treated with 
adenoviral mda-7 had decreased tumor vascularization when compared to control tumors 
[64].  IL-24 protein has been shown to selectively inhibit endothelial cell differentiation, 
exhibiting direct anti-angiogenic actions [69].  In addition, IL-24 secreted by normal human 
prostate cells treated with Ad.mda-7 also inhibited the invasion of cancer cells that express 
the IL-24 receptors [70].  IL-24 causes a G2/M block by increasing the accumulation of 
melanoma cell lines in S phase in-vitro, as well as having an anti-proliferative affect [71].  It 
also has been shown in glioma [72], prostate and ovarian carcinoma [73, 74], breast cancer 
[75], and non-small cell lung cancer [76, 77] that IL-24 generation of reactive oxygen species 
had a radiosensitization effect on those cells. 
Accordingly, IL-24 appears to act as a tumor suppressor in melanoma and other 
cancers by a variety of mechanisms, and is currently being studied in clinical trials for its 
potential therapeutic usefulness.  In addition to its direct tumor suppressive effects, several 
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studies confirm a bystander effect of the secreted protein from Ad.mda-7 gene therapy (55) 
such that IL-24 secreted from Ad.mda-7 transfected cells was shown to induce cell death in 
non-transfected tumor cells.  The Ad.mda-7 gene construct has been used in Phase I/II gene 
therapy clinical trials [56, 78-80] through intratumoral injection of the Ad.mda-7 construct 
[78, 79].  In the phase I/II clinical trials IL-24 was well tolerated and showed considerable 
apoptotic activity in injected lesions [78, 81-83].  Clinically significant responses including 
tumor regression were found with repeat injections. 
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Figure 3. IL-24 associated pathways in cancer cell apoptosis.  Summary of signaling pathways related to IL-
24 activity. 
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Preliminary data and Rationale for Hypothesis 
Preliminary data from our laboratory revealed by FACS analysis that stimulation of 
A375, a melanoma cell line, with high doses of IL-2 resulted in endogenous production of 
IL-24 in a dose dependent manner (data not shown).  However, another melanoma cell line, 
MeWo, did not show any upregulation of IL-24 following IL-2 treatment.  Subsequently, 
three out of five melanoma cell lines analyzed showed an increase in IL-24 protein 
production and secretion of IL-24 in response to treatment with high dose IL-2.  Our 
laboratory has published in vitro data in normal peripheral blood mononuclear cells (PBMC) 
that show that PHA stimulation results in IL-2 secretion; this appears to stabilize IL-24 
mRNA resulting in increased protein production [84].  It is possible that this mechanism also 
occurs in melanoma cells.  These observations seemed to suggest that that there may exist a 
mechanism by which IL-2 acts directly on the melanoma cells in responsive patients instead 
of solely mediating its effects through the immune system. 
Given these data, we propose that one mechanism by which high dose IL-2 is able to 
generate a durable response in these patients is through direct activation via the IL-2 receptor 
on melanoma cells of IL-24 mediated tumor growth suppression or apoptosis.  Several 
articles in the literature report that IL-2 receptor chains are present on the surfaces of both 
human and murine cutaneous melanoma cells [85-90].  IL-2Rβ in particular has been 
identified in a number of cancer cell lines including small cell lung cancer and squamous cell 
carcinoma of the head and neck [91, 92], and melanoma.  The mechanisms of IL-24 
antitumor growth effects have been extensively studied by several groups.  Based on this, we 
hypothesize that a subset of patients whose melanoma cells express IL-24 and IL-2 receptor 
will have a better response to IL-2 therapy due to IL-24 mediated growth control, and thus 
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expression of IL-24 and IL-2R may be useful as potential positive predictive markers to 
identify patients who are suitable candidates for IL-2 therapy.  With this approach to 
treatment, therapy can then be targeted to the specific patients who will respond, while the 
patients who are unlikely to gain any benefits from IL-2 therapy will be spared its toxicity 
and can be directed to alternative treatments.  Thus, we seek to improve the quality of life for 
melanoma patients.  We hope that in identifying a potential predictive marker, this project 
will provide a prognostic test for the therapeutic efficacy of IL-2 therapy in melanoma 
patients. 
 The goal of this project was to mimic the conditions present in high dose IL-2 
patients during therapy.  Those patients receive approximately 600,000-720,000 IU/kg per 
dose every 8 hours infused intravenously over 15-20 minutes on days 1 to 5 and 15 to 19 
with a maximum of 28 doses per course [93, 94].  A study was performed examining 
different cytokine levels in patients’ serum at various time points during high dose IL-2 
therapy.  It showed that peak IL-2 levels in the serum of these patients averaged around 4000 
U/ml and remained well above 1000 U/ml after the 4th dose [95, 96].  Based on these data, 
we feel confident that 1000U/ml is a reasonable conservative dose at which to test the effects 
of high dose IL-2 on melanoma cells. 
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Materials and Methods 
 
Cell lines and cell culture  
We obtained two human metastatic melanoma cell lines, A375 and MeWo, from the 
American Type Culture Collection (Rockville, MD).  The WM1341, WM793, and WM35 
human primary melanoma cell lines were developed by Dr. Meenhard Herlyn (Wistar 
Institute, Philadelphia, PA) [97] and were obtained from Dr. Robert Kerbel (University of 
Toronto, Toronto, Ontario, Canada) [98, 99].  All melanoma cell lines used were maintained 
in RPMI 1640 medium supplemented with 100 U/mL of penicillin, 100 mg/mL of 
streptomycin, 2 mM L-glutamine, and HEPES buffer with 4% fetal bovine serum (all 
purchased from Life Technologies, Inc., Grand Island, NY).  Experiments were run in 
supplemented RPMI with 2% charcoal stripped FBS (description below) unless otherwise 
indicated.   
 
Charcoal stripped fetal bovine serum 
Fetal bovine serum (Life Technologies, Inc) was charcoal stripped to remove 
endogenous hormones and steroids and reduce any background levels of IL-24 in cell lines 
grown in serum caused by nonspecific activation from serum components.  This was 
achieved by incubating the serum overnight at 4 degrees C with a mixture of charcoal, 
dextran, sucrose, magnesium chloride, and HEPES buffer from Sigma-Aldrich (St. Louis, 
MO) following the manufacture’s protocol. 
 
 
 16
Reagents  
IL-2 was obtained from Chiron (formerly Cetus) (Emeryville, CA).  IL-2 was used at 
1000 U/ml in all experiments described for this publication unless otherwise noted.  IL-2 has 
an initial rapid redistribution phase half-life of approximately 13 minutes followed by a 
slower elimination phase half-life of 85 minutes in serum.  As discussed in the introduction, 
the goal of this project was to mimic the conditions present in high dose IL-2 patients during 
therapy.  Studies of high dose IL-2 patient serum showed that peak IL-2 levels in the serum 
averaged around 4000 U/ml and remained well above 1000 U/ml after the 4th dose [95, 96].  
Based on these data, we feel confident that 1000U/ml is a reasonable conservative dose at 
which to test the effects of high dose IL-2 on melanoma cells.  IL-15 was purchased from 
eBioscience (San Diego, CA).  7G11, an anti-IL-24 mouse monoclonal antibody (Introgen 
Therapeutics, Houston, TX), was used for Western blotting and for blocking IL-24 during 
growth assays.  Mouse anti-human IL-2 monoclonal antibodies were purchased from BD 
BioSciences (San Jose, CA).  Anti-IL-2 receptor (IL-2Rα, IL-2Rβ, and IL-2Rγ) antibodies 
were purchased from R&D Systems (Minneapolis, MN).  Preimmune normal mouse IgG 
(Sigma-Aldrich, St. Louis, MO) was used as a negative control for receptor blocking studies.  
Anti-actin antibody from Santa Cruz Biotechnology (Santa Cruz, CA) was used as a standard 
loading control for all Western blot staining.  Lipopolysaccharide (LPS) was purchased from 
Sigma-Aldrich (St. Louis, MO).  
 
Whole cell extracts and Western blotting analysis 
Cells were treated with brefeldin A (Sigma-Aldrich, St. Louis, MO) at 10ug/ml four 
hours prior to harvesting, washed with cold PBS, and subsequently harvested into PBS.  Cell 
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pellets were then resuspended in protein lysis buffer (140 mM NaCl, 25 mM Tris HCl pH 
7.4, and 1% NP-40) with fresh protease inhibitor cocktail (BD Biosciences, San Jose, CA). 
The supernatants were collected after agitation and protein concentration was measured by 
Bradford Assay (BioRad).  Proteins were separated by SDS-PAGE, transferred to a 
nitrocellulose membrane (Amersham-Hybond ECL – GE Healthcare, Piscataway, NJ), and 
blocked for 1 hour in 5% nonfat milk in PBS.  Primary antibody was diluted in 5% nonfat 
dry milk/PBS/ 0.1% Tween and incubated overnight at 4°C.  This was followed by a 45 
minute incubation with an appropriate horseradish peroxidase labeled secondary antibody, 
also diluted in 5% nonfat dry milk/PBS/ 0.1% Tween. Membranes were then developed with 
enhanced chemiluminescence reagents (Amersham Pharmacia Biotech, Piscataway, NJ).  
Western blot band protein quantification was performed using densitometry analysis with 
Scion Image software (Scion Corporation).  Differences in protein levels between treatment 
conditions were determined by normalizing test proteins to beta-actin controls within each 
sample.  
 
Detection of secreted IL-24 protein  
Melanoma cells were plated at 1 × 106 cells/mL and cultured in supplemented RPMI-
1640 medium (Invitrogen, Carlsbad, CA) + 2% charcoal stripped FBS with IL-2 added at 
1000U/ml.  Supernatants were harvested at 24 hours and secreted IL-24 levels were 
determined with an ELISA test kit (R&D Systems, Inc., Minneapolis, MN) according to the 
manufacturer’s protocol. Reference standards for the ELISA were resuspended in cell culture 
medium. The amounts of IL-24 were quantified based on a standard curve determined by 
means of optical density readings measured at 450 nm with a reference of 550 nm on an 
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ELISA plate reader (Dynex Technologies, Chantilly, VA). The mean values at each time 
point were then used directly for the analysis reported. 
 
RNA Isolation 
RNA extraction from melanoma cells was accomplished using the Qiagen RNAeasy 
mini kit protocol.  Total RNA was extracted from melanoma cells by first lysing and 
homogenizing the tissue by passing the cells back and forth through a syringe and needle.  
Ethanol was added to the lysates, and the samples were applied to the RNAeasy spin 
columns.  Total RNA was isolated following the manufacturers protocol (Qiagen, Valencia, 
CA).  DNase I treatment was accomplished by adding RNase-free DNase I (Sigma-Aldrich, 
St. Louis, MO) to the samples, incubating at 37°C for 30 minutes, and then heating at 75°C 
for 10 minutes to disable the DNAse I. 
 
Real-Time Quantitative RT-PCR – Probe-based assay 
Real-time qPCR assays were performed in the Quantitative Genomics Core 
Laboratory (QGCL) at The University of Texas Health Sciences Center in Houston, Texas. 
All real-time qPCR assays used in this publication were designed and validated by QGCL 
staff to ensure they pass the minimum requirements for efficiency, sensitivity and selectivity.  
Their protocol [100] follows: 
“cDNA was synthesized in 5 µl (384-well plate) total volume by the addition of 3 
µl/well RT master mix consisting of: 400 nM assay-specific reverse primer, 500 μM 
deoxynucleotides, Superscript II buffer and 1 U/µl Superscript II reverse transcriptase 
(Invitrogen, Carlsbad, CA), to a  96-well plate (ISC Bioexpress, Kaysville, UT) or 384-well 
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plate (Applied Biosystems, Foster City, CA) and followed by a 2 µl volume of sample (25 
ng/µl). Each sample was assayed in triplicate plus a control without reverse transcriptase to 
access DNA contamination levels. Each plate also contained an assay-specific sDNA 
(synthetic amplicon oligo) standard spanning a 5-log template concentration range and a no 
template PCR control, also put into RT master mix with reverse transcriptase. Each plate was 
covered with Biofilm A (Bio-Rad, Hercules, CA) and incubated in a PTC-100 (96) or DYAD 
(384) thermocycler (Bio-Rad, Hercules, CA) for 30 minutes at 50°C followed by 72˚C for 10 
min.  PCR master mix, 15µl/well, was added directly to the 5 µl RT volume. Final 
concentrations for the PCR were 400 nM forward and reverse primers (IDT, Coralville, IA), 
100 nM fluorogenic probe (Biosearch Technologies, Novato, CA), 5 mM MgCl2, and 200 
μM deoxynucleotides, PCR buffer, 150 nM SuperROX dye (Biosearch Technologies, 
Novato, CA) and 0.25 U JumpStart Taq polymerase per reaction (Invitrogen, Carlsbad, CA), 
final concentrations. RT master mixes and all RNA samples and DNA oligo standards were 
pipetted by a Tecan Genesis RSP 100 robotic workstation (Tecan US, Research Triangle 
Park, NC); PCR master mixes were pipetted utilizing a Biomek 2000 robotic workstation 
(Beckman, Fullerton, CA). Each assembled plate was then covered with optically clear film 
(Applied Biosystems, Foster City, CA) and run in a 7900 real-time instrument using the 
following cycling conditions: 95°C, 1 min; followed by 40 cycles of 95°C, 12 sec and 60°C, 
30 sec. The resulting data were analyzed using SDS 2.3 (7900) software (Applied 
Biosystems, Foster City, CA) with FAM reporter and ROX as the reference dye. 
Synthetic, PAGE purified DNA oligos used as standards (sDNA) encompassed at 
least the entire 5’ – 3’ amplicon for the assay (Sigma-Genosys, The Woodlands, TX). Each 
oligo standard was diluted in 100 ng/µl E. coli tRNA-H2O (Roche Diagnostics, Indianapolis, 
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IN) and spanned a 5-log range in 10-fold decrements starting at 0.8 pg/reaction. It has been 
shown for several assays that in vitro transcribed RNA amplicon standards (sRNA) and 
sDNA standards have the same PCR efficiency when the reactions are performed as 
described above with PCR amplicons of less than 100 bases in length (G.L. Shipley, personal 
communication). 
Due to the inherent inaccuracies in quantifying total RNA by absorbance, the amount 
of RNA added to an RT-PCR from each sample was more accurately determined by 
measuring the amount of at least one transcript that was invariant across all samples. The 
final data were normalized to b-actin.  Due to the high abundance of the 3 ribosomal RNAs, a 
second set of samples diluted 1/500-fold was made in 100 ng/µl E. coli tRNA-H2O for each 
sample.  The final data are presented as the molecules of unknown transcript/molecules of 
normalizer transcript x 100 and expressed as the percent of the normalizer transcript. Unless 
otherwise stated, quantities for unknown samples were obtained from an internal standard 
curve run on each plate. 
For Roche UPL probe-based or SYBR Green I dye-based assays, the dCt method was 
used for data analysis comparing test samples to an appropriate control ‘calibrator’ sample to 
determine a fold difference between the calibrator sample and the other unknown samples. 
It is necessary to validate the hits using a second assay. Validation is based on Roche UPL 
hydrolysis probe assays. The determination of PCR efficiency and lowest limit of detection 
(LOD) was performed using template from a PCR diluted 100-fold into 100 ng/µl E. coli 
tRNA-H2O. Seven log10 dilutions were made in diluent and a standard curve was produced 
using standard cycling conditions (see above for Taqman probes). From this curve, a PCR 
efficiency and LOD were determined.” 
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Growth suppression assays 
Cells were plated at 5 x 105 cells per well in 24 well plates.  Cells were serum starved 
overnight and then treated with RPMI + 2% charcoal stripped FBS with or without IL-2 at 
1000U/ml and other indicated conditions at day 0.  Each condition was performed in 
triplicate.  Cells were then trypsinized and collected, and viable cells were counted using a 
0.2% Trypan blue dye exclusion assay at days 2 through 6 to assess cell growth.  Mean 
values were determined for each condition and used for analysis. 
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Table 2. IL-24 and IL-2R chain PCR primers and efficiency 
 
hIL-24 (IL-24) 
 
accession #: 
NM_006850 
1484(+) AAGCAGATCCTCAATAAACATTTC 
1556(-) ACCAAGGGAAAGGGATGATG 
1511(+) FAM-TCCCACCCACACTCGCCAGC-BHQ1 
PCR amplicon length =77 bases 
Lowest limit of detection = 190 copies 
PCR efficiency = 98% 
 
hIL-2Ra (IL2RA) 
 
accession #: 
NM_000417 
 
1061(+) CTAAATGGTCGCCCAGGAG 
1128(-) TGTGATGTGACTTCAGAGCTT 
1081(+) FAM-CATCCGTTGTGCTTGCCTGCGT-BHQ1 
PCR amplicon length = 90 bases 
Lowest limit of detection = 160 copies (RT-PCR) 
PCR efficiency = 99% 
 
hIL-2Rb (IL2RB) 
 
 accession #: 
NM_000878 
 
2037(+) CTCCCTCGTTAATCACAGGAT 
2124(-) AGGACTGATATTGGTGAATAGCT 
2068(+) FAM-TAGGCTCAGAAGCATCGCTCCTCT-BHQ1 
PCR amplicon length = 90 bases 
Lowest limit of detection = 160 copies (RT-PCR) 
PCR efficiency = 99% 
 
hIL-2Rg (IL2RG)  
 
accession #: 
NM_000206 
 
380(+) CCACCTCTACCAAACATTTGTT 
450(-) GCATCTGTGTGGCCTGTC 
411(+) FAM-CAGGACCCACGGGAACCCAGG-BHQ1 
PCR amplicon length = 80 bases 
Lowest limit of detection = 180 copies (RT-PCR) 
PCR efficiency = 99% 
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siRNA Assay 
For these experiments, siGENOME SMARTpool for human IL-24 and siGENOME 
Non-Targeting siRNA Pool were purchased from Dharmacon, Inc. (Chicago, IL).  
Oligofectamine was obtained from Invitrogen (Carlsbad, CA).  Melanoma cells were serum 
starved overnight and then transfected with 2 nM IL-24 siRNA or control siRNA in 
OptiMEM media.  Fresh RPMI + 4% FBS was added 4 hours after the transfection.  Cells 
were transfected a second time 24 hours after the initial transfection and harvested 24 hours 
later.  RNA was extracted and analyzed for IL-24 mRNA levels by RT-PCR.  For growth 
suppression assays, supplemented RPMI + 2% CSFBS media and IL-2 were added 24 hours 
after the second transfection.  This time point was designated day 0, and viable cells were 
counted at day 6 using the Trypan blue dye exclusion assay. 
 
Statistical Analysis 
We determined means and standard errors for each of the variables and used the 
Student’s t test to evaluate the statistical significance of the experimental results. All 
experiments were performed at least three times unless otherwise indicated. Statistical 
significance was set at P < 0.05. 
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Results 
 
IL-24 message is present in some melanoma cells 
 Melanoma tumors are not homogeneous assemblages of cells.  It has been observed 
that IL-24 protein is expressed by many nevi and primary melanoma tumors.  One group 
looked at IL-24 expression by immunohistochemistry in various tumors and found that 100% 
of normal melanocytes and benign nevi and 71% of primary melanomas tested were positive 
for IL-24.  This protein expression is often subsequently lost during melanoma tumor 
invasion and progression and can be undetectable in advanced metastatic disease [101-103].  
Only 35% of metastatic melanomas examined had IL-24.  Given this heterogeneity among 
melanoma tumors we hypothesize that only some melanoma tumors and cell lines will have 
IL-24 message. 
Five melanoma cell lines representing various stages of disease and mutation status 
(Table 3) were examined by RT-PCR for the presence of IL-24 message.  A375, WM1341, 
and WM793 were shown to possess IL-24 message while WM35 and MeWo had very low or 
undetectable levels of IL-24 mRNA (Figure 4).  Data was normalized to beta-actin mRNA 
levels. 
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Table 3.  Human melanoma cell line descriptions 
 
Cell line Source tissue BRAF/NRAS Status 
A375 
 
Skin metastasis Mutant / wild type 
WM1341 1° nodular melanoma, early stage Wild type / mutant 
WM793 1° superficial spreading melanoma, 
vertical growth phase, sternum, stage 1
Mutant / wild type 
WM35 1° superficial spreading melanoma, 
scalp/neck, stage 1 
Mutant / wild type 
MeWo Lymph node metastasis – late stage Wild type / wild type 
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Figure 4.  Some melanoma cells have message for IL-24.  Cells were grown in FBS + 4% RPMI.  
Total RNA was extracted and analyzed for IL-24 mRNA by RT-PCR.  Each sample was assayed in 
triplicate plus a control without reverse transcriptase to assess DNA contamination levels.  Standard 
deviations are displayed above. 
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Basal IL-24 levels in melanoma cells are affected by serum components 
 To study the effects of cytokines in vitro it is often helpful to use charcoal stripping, 
an absorptive process, to minimize the presence of endogenous hormones, growth factors, 
and cytokines in serum.  We hypothesized that any effects of treatment with IL-2 on IL-24 
protein would be better exposed if background levels of IL-24 produced by cells, probably to 
some extent due to nonspecific activation from serum components, were decreased. 
Melanoma cells grown in RPMI + 2% FBS were compared to those grown in RPMI + 
2% charcoal stripped FBS.  Those grown in charcoal stripped media exhibited significantly 
less background IL-24 than those grown in non-stripped media, and the effects of IL-2 
treatment were more easily visualized (Figure 5).  These melanoma cells are sensitive to 
components within the serum, and the decreased basal levels of IL-24 when grown in the 
charcoal stripped media allow for a better sense of the impact our treatments have on the 
cells. 
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Figure 5. Charcoal stripped FBS media decreases background levels of IL-24. Cells were serum starved 
overnight and then grown for 24 hours in RPMI + 2% FBS or RPMI + 2% charcoal stripped FBS (CSFBS) 
under varying conditions.   Brefeldin A was added 4 hours prior to harvesting the cells.  Whole cell lysates were 
analyzed by Western blot for intracellular IL-24 and actin. 
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IL-2 upregulates IL-24 protein production and secretion in 3/5 melanoma cell lines 
 Our laboratory has published data that shows IL-2 stimulation triggers IL-24 
production in PBMC [84].  Preliminary unpublished data showed by FACS analysis that IL-2 
at high doses caused increased expression of IL-24 in A375 cells in a dose dependent 
manner, but no increase was seen in MeWo cells.  We therefore hypothesized that in cell 
lines containing IL-24 mRNA, stimulation with IL-2 might also result in upregulation of IL-
24 protein expression.  
Melanoma cells were treated with high dose IL-2 at 1000U/ml in RPMI + 2% 
charcoal stripped FBS for 24 hours.  It was discovered in early experiments that three of the 
cell lines actively secreted IL-24 protein, in some cases at levels high enough to be detected 
in the unconcentrated supernatant by Western blot analysis (data not shown).  Therefore, in 
subsequent experiments all cells were treated with brefeldin A at 10ug/ml to prevent protein 
secretion for 4 hours prior to harvesting in order to better elucidate the levels of IL-24 being 
produced by our cells.  LPS was used as a positive control since melanoma cells are known 
to respond via the Toll-Like Receptor-4 (TLR4); in monocytes and macrophages which 
express TLR4, IL-24 expression can also be induced by treatment with LPS [84].  
Representative Western blots are shown here for the three responsive cell lines.  A375, 
WM1341, and WM793 were all found to have basal levels of IL-24 protein.  This result was 
anticipated from the previous IL-24 mRNA data and confirmed our hypothesis that IL-24 is 
constitutively present in some cells.  These same cell lines also showed consistently 
increased levels of IL-24 protein when treated with high dose IL-2 (1000U/ml) as compared 
to cells cultured in media alone (Figure 6), and this increase was shown to be statistically 
significant.  A375 exhibited an average increase in IL-24 levels of 43.0% (p=0.01) when 
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treated with IL-2.  WM1341 showed an increase of 31.6% (p<0.01) and WM793 had an 
increase of 27.4% (p<0.01).  WM35 and MeWo cells did not produce detectable levels of IL-
24 regardless of treatment with IL-2 (data not shown).  The actual percent increase in IL-24 
levels varied between cell lines and experiments, but within the 3 responsive cell lines IL-2 
stimulated cells always demonstrated increased levels of IL-24 protein.  Each cell line was 
tested at least three times. 
Based on cDNA analysis, soluble human IL-24 was predicted to be a monomeric 18 
kDa protein [84].  However, data from several sources show that IL-24 protein derived from 
the HEK-293-IL-24 mammalian expression system exists as several different monomeric 
species with molecular weights ranging from approximately 18 to 32 kDa [104, 105].  These 
data point toward the possibility of post-translational modifications to the protein.  Several  
groups, including our laboratory, have found that soluble IL-24 is N-glycosylated [106, 107], 
and secreted IL-24 is thought to contain three distinct N-glycosylation sites (49) which 
accounts for the immunoreactivity of multiple bands that our IL-24 antibody detects during 
Western blot analysis.  IL-24 protein often appears or 2 or 3 separate bands in our blots 
depending on how far out the gels are run. 
ELISA analysis of the cell lines showed that A375, WM1341, and WM793 cells 
secreted detectable levels of IL-24 into the supernatant constitutively, and that those cells 
treated with IL-2 for 24 hours secreted significantly more IL-24 protein than their untreated 
counterparts (Figure 7).  IL-2 treatment caused an increase in IL-24 secretion in A375 by 
56% (p=0.02), in WM1341 by 82% (p<0.01), and in WM793 by 40% (p=0.01).  WM35 and 
MeWo cells do not secrete any detectable levels of IL-24.  Charcoal stripped FBS media was 
included as a control. 
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In order to confirm that the increases we observed in IL-24 levels were specifically 
due to the actions of IL-2, the IL-2 was neutralized by preincubating with a mouse-anti-hIL-2 
antibody for 1 hour at room temperature prior to stimulating the cells.  A representative 
Western blot from the IL-24 positive cell line WM1341 is shown (Figure 8).  Neutralization 
of the IL-2 resulted in a reversal of its effects on IL-24 and was enough to bring IL-24 levels 
down to below baseline.  This indicates that the elevations of IL-24 levels in these cells are a 
direct result of treatment with high dose IL-2. 
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Figure 6. High dose IL-2 upregulates IL-24 expression in some melanoma cells – Cells were plated in 
35mm dishes and then incubated with media alone, IL-2 (1000U/ml), or LPS (100ng/ml) for 24 hours.  
Brefeldin A was added 4 hours prior to harvesting the cells to halt protein secretion.  a) Whole cell lysates were 
separated on a 12% SDS-PAGE gel and probed with 7G11 (mouse anti-human IL-24 antibody) and an anti-
actin antibody as a protein loading control  b) Western blot bands were quantified by normalizing to actin and 
then graphed as % of media control.  Percent change and p-values were calculated by combining data from at 
least three experiments. 
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Figure 7.  IL-24 is secreted by some melanoma cells.  1 x 106 cells were plated in 35mm dishes and 
serum starved overnight.  Cells were then cultured in RPMI + 2% CSFBS with or without IL-2 (1000 
U/ml).  Supernatant was harvested at 24 hours and analyzed by ELISA in triplicate for secreted IL-24. 
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Figure 8.  IL-2 upregulation of IL-24 can be neutralized with anti-IL-2 antibody.  Shown here in a 
representative blot, IL-2 was preincubated with a neutralizing mouse-anti-hIL-2 antibody for 1 hour at 
room temperature before being added to WM1341 cells.  A) Cells were harvested at 24 hours and 
analyzed by Western blot.  B) Protein quantitation was performed by normalizing bands to actin.  
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 Melanoma cells have IL-2R mRNA  
Given our evidence that IL-2 has a direct biological effect on some melanoma cells, 
we hypothesized that the IL-2 receptor must therefore be present on these cells.  IL-2 
mediates its effects on T cells by binding and signaling through the IL-2 receptor [108].  The 
receptor complex on lymphocytes is composed of three chains - α, β, and γ which in different 
combinations form intermediate and high affinity receptors for IL-2 [109, 110].  Precedence 
exists for our hypothesis that some of our melanoma cells must contain one or more chains of 
the IL-2 receptor.  Several articles in the literature report that IL-2 receptor chains are present 
on the surfaces of both human and murine cutaneous melanoma cells (85-90).  IL-2Rβ in 
particular has been identified in a number of cancer cell lines including small cell lung cancer 
and squamous cell carcinoma of the head and neck (91;92), and melanoma.   
Each of our five cell lines was found to have measurable IL-2Rβ and IL-2Rγ mRNA 
at varying amounts when analyzed by RT-PCR (Figure 9).  IL-2Rα message was not 
detected in any of these cell lines.  However, the IL-2Rα chain serves only to stabilize the 
interaction between IL-2 and its receptor; IL-2Rα is not required for IL-2R signal 
transduction [111].  IL-2Rβ and γ form an intermediate affinity receptor for IL-2.  These 
findings support our hypothesis that IL-2 can have a direct effect on melanoma cells by 
signaling through its receptor.   
To confirm that IL-2 signals specifically through its receptor to upregulate IL-24 in 
these cells, the IL-2 receptor was first blocked by preincubating WM1341 and A375 cells 
with antibodies specific for each of the three IL-2 receptor chains for 1 hour at room 
temperature and then stimulating with IL-2 (Figure 10).  All antibodies were use at the 
concentrations suggested by the manufacturer, R&D Systems.  As predicted, blocking with 
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antibodies to the IL-2 receptor chains prior to adding the IL-2 resulted in a decrease in IL-24 
levels as compared to unblocked cells.  This inhibition was seen most dramatically with the 
blocking of IL-2Rβ suggesting that the IL-2Rβ chain is essential for IL-2 upregulation of IL-
24 expression.  Mouse IgG was used at 60 ug/ml, a dose equal to the highest concentration of 
IL-2R antibody used, as a negative control antibody in order to rule out the effects of any 
nonspecific blocking.  A representative Western blot from the IL-24 positive cell line 
WM1341 is shown. 
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Figure 9.  IL-2Rβ and IL-2Rγ chain mRNA is present in melanoma cell lines.  Total RNA was extracted 
from 5 cell lines and analyzed by RT-PCR for IL-2 receptor chain message. 
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Figure 10. IL-2 mediated IL-24 production is abolished by blocking the IL-2R.  Cells were preincubated 
with blocking antibodies against the three IL-2 receptor chains (α, β, and γ) at the concentrations noted per the 
manufacture’s protocol for 1 hour at room temperature prior to the addition of IL-2 (1000U/ml).  mIgG was 
used as an antibody negative control.  Cells were harvested at 24 hours and analyzed by Western blot.  A 
representative blot is shown here in WM1341 cells. 
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IL-15 upregulates IL-24 expression in melanoma cell lines 
Once the presence and importance of IL-2Rβ on these melanoma cells were 
established, the next logical step was to determine if the upregulation of IL-24 is specific to 
stimulation with IL-2.  Utilization of other cytokines which also signal through the IL-2R 
chains was considered.  IL-15 was of particular interest because it is the only cytokine known 
to share both the IL-2Rβ chain and common gamma chain [112, 113].  Thus, we 
hypothesized that stimulating cells with IL-15 would also have an effect and result in 
increased levels of IL-24 expression.  
Cells were stimulated with IL-15 (500 U/ml) for 24 hours and cell lysates were 
analyzed by Western blot analysis for IL-24 protein.  IL-2 and LPS stimulated cells were 
included as controls.  All three IL-24 positive cell lines showed upregulation of IL-24 when 
treated with IL-15 (Figure 11).  In A375 and WM1341, this increase was even higher than 
that seen with high dose IL-2 stimulation.  This data together with the IL-2 receptor blocking 
experiment confirms the significance of IL-2Rβ for IL-24 upregulation. It also points toward 
the potential therapeutic use of IL-15 as a treatment for melanoma. 
 40
 
 
 
 
Figure 11. IL-15 upregulates IL-24 expression in some melanoma cells.  Cells were incubated with media 
alone, IL-2 (1000U/ml), IL-15 (500U/ml), or LPS (100ng/ml) for 24 hours.  Brefeldin A was added 4 hours 
prior to harvesting the cells to halt protein secretion.  a) Cell lysates were separated on a 12% SDS-PAGE gel 
and probed with 7G11 and an anti-actin antibody as a protein loading control b) Western blot bands were 
quantified by normalizing to actin.  Data is presented as % of IL-24 expression in media control. 
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IL-2 causes growth suppression in some melanoma cells  
RT-PCR showed that IL-2Rβ is present on these melanoma cell lines.  It has been 
reported that several other cancers including squamous cell carcinoma, renal cell carcinoma, 
and gastric carcinomas are growth inhibited by IL-2 signaling specifically through the IL-
2Rβ chain [114, 115].  We hypothesized that this also might be the case in the subset of 
melanoma patients who respond to high dose IL-2 therapy and that these patients might be 
represented by some of our melanoma cell lines.   
Cells for each condition were plated in triplicate in 24 well plates and grown in RPMI 
+ 2% CSFBS with or without IL-2 (1000 U/ml) added at day 0.  MTT assays were initially 
attempted but failed to show any differences in growth.  Because the MTT assay relies on 
functional mitochondria to break down the tetrazolium bromide, it is not an ideal assay for 
melanoma cells which are known to have mitochondrial mutations [116-118].  Instead, cells 
were counted and cell viability assessed by Trypan blue dye exclusion assay on days 2 
through 6 (Figure 11a).  In WM1341 and WM793, cells treated with IL-2 had significantly 
fewer viable cells by day 4 (p ≤ 0.01).  A375 showed statistically significant growth 
suppression with IL-2 by day 5 (p = 0.04).  By day 6, IL-2 treated cells exhibited 18-32% 
less growth than untreated cells.  The growth of the IL-24 negative cell lines WM35 and 
MeWo was unaffected by treatment with IL-2.  Although WM35 cells had the highest level 
of IL-2Rβ (Figure 9), IL-2 had no affect on its growth.  This implies that IL-2 mediated 
growth suppression is dependent on the IL-24 status of the cells. 
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IL-2 mediated growth suppression is dependent on IL-24 
As discussed in the introduction, the tumor suppressive characteristics of IL-24 have 
been well documented.  IL-24 has been shown to cause tumor specific growth suppression 
and apoptosis both in vitro and in vivo, including lung, pancreatic, and breast cancer cells, 
while demonstrating no apparent toxicity to normal cells [56, 64, 65, 119-125].   Data from 
our laboratory further demonstrates IL-24’s cytotoxicity to human melanoma cell lines.  
These data all support the tumor suppressor activity ascribed to IL-24 [126].  Based on our 
data which show that treatment with IL-2 causes increased IL-24 protein production and 
secretion in some melanoma cell lines, it is reasonable to conjecture that these amplified 
levels of IL-24 might subsequently cause growth suppression in those cell lines.  According 
to the literature, melanoma cells transduced with Ad-mda7 (introduction of the IL-24 gene 
via adenoviral vector) can secrete IL-24 protein which then plays a tumor selective cytotoxic 
bystander role [70]. 
Therefore, we hypothesized that the growth suppression seen in response to IL-2 
(Figure 12a) is IL-24 dependent.  Consequently, blocking the effects of the secreted IL-24 
with an anti-IL-24 monoclonal antibody should reduce the growth suppression observed in 
IL-2 responsive cells.  In addition we hypothesized that blocking the production of IL-24 
directly by silencing IL-24 mRNA should also inhibit the growth suppression seen with IL-2 
stimulation. 
Once again, cell viability was assessed by Trypan blue dye exclusion assay.  A375 
and WM1341 cells treated with 7G11 (an anti-IL-24 monoclonal antibody) to block the 
effects of secreted IL-24 displayed growth curve patterns similar to those cells grown in 
media alone without IL-2 (Figure 12b), i.e. no significant growth suppression was detected.  
 43
Cells were also treated with mIgG with or without IL-2 as controls; these cells behaved like 
their non-mIgG treated counterparts.  The addition of 7G11 had no effect on the growth of 
WM35 and MeWo cells which do not express IL-24 protein.  These data indicate that IL-2 
mediated growth suppression in melanoma cell lines is directly due to IL-24. 
In order to directly block IL-24 production, two IL-24 positive cell lines (A375 and 
WM1341) and one IL-24 negative cell line (WM35) were treated with IL-24 siRNA or a 
non-coding siRNA negative control for 48 hours prior to the addition of high dose IL-2 on 
day 0.  Cell viability was assessed at day 6 as shown in Figure 12c.  Although it is 
understood that the silencing effects of the siRNA transfection last only up to 72 hours, even 
this initial temporary inhibition of IL-24 production demonstrated a noticeable effect on cell 
growth.  These growth suppression assays show that in IL-24 positive cell lines, silencing IL-
24 at the mRNA level counteracts the IL-2 mediated growth suppressive effects previously 
observed (Figure 12c).  In these cell lines, there was no significant difference seen between 
the IL-24 silenced cells that were cultured with IL-2 and those without IL-2.  There was a 
loss of total cell number due to toxicity in both the control oligofectamine treated cells and 
non-coding siRNA treated cells, but IL-2 maintained its growth suppressive effects in both of 
these groups (p≤0.05).  In WM35, an IL-24 negative cell line, treating with IL-24 siRNA had 
no effect on growth between IL-2 treated and non-treated cells.  IL-24 knock-down was 
verified by RT-PCR for IL-24 message in cells transfected with either non-coding control 
siRNA or IL-24 siRNA (Figure 13).  These data also confirm that IL-2 mediated growth 
suppression is directly dependent on IL-24. 
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Figure 12.  Effects of IL-2 on Melanoma Cell Growth by Trypan Blue Assay.  Cells were plated in 24 well 
plates with each condition in triplicate.  Cells were serum starved overnight and then stimulated on day 0. The 
table indicates the % decrease in cell growth observed when treated with IL-2 as compared to cells grown in 
media alone.  A. IL-2 effects on melanoma cell growth.  B. Blocking the effects of secreted IL-24 with 7G11 
(mouse-anti-IL-24) antibody.  C. siRNA transfected melanoma cell growth at day 6.  All data is presented as % 
growth inhibition by IL-2 compared to cells grown in media alone (1-(IL-2 treated cells/media)). 
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Figure 13. IL-24 siRNA effectively knocks down IL-24 mRNA in melanoma cell lines.  Cells were 
harvested 24 hours after treatment with siRNA and analyzed for IL-24 and actin mRNA by RT-PCR.  IL-24 
mRNA data is shown as % b-actin. 
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 IL-15 causes growth suppression in A375 cells 
 Our data has established that in A375, WM1341, and WM793 cells IL-2 causes 
growth suppression in an IL-24 dependent manner.  Stimulating those cell lines with IL-15 
also results in upregulation of IL-24 protein expression.  It is known that IL-15 signals 
through the same IL-2Rβ and IL-2Rγ chains as IL-2.  Thus, we hypothesized that IL-15 
should also cause growth suppression in IL-24 positive cell lines.  This hypothesis was 
investigated in the A375 melanoma cell line.  The experimental design was identical to the 
growth suppression assays previously described and were done in parallel with IL-2.  Cells 
were grown in media alone, IL-15 (500 U/ml), or IL-2 (1000 U/ml).  Results showed that 
cells treated with IL-15 demonstrated significant growth suppression of approximately 19-
25% over days 4 through 6 (p=0.02 by day 4).  These results are comparable to those cells 
treated with IL-2 (Figure 14). 
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Figure 14.  IL-15 causes growth suppression in A375 cells by day 4.  Cells were plated in 24 well plates with 
each condition in triplicate.  Cells were serum starved overnight and then stimulated on day 0. 
 51
Serum levels of IL-24 in high dose IL-2 patients 
We hypothesized that because IL-2 upregulates IL-24 protein expression in some 
cells, it might be possible to measure any subsequent systemic changes in the serum of 
patients.  Dr. Laslo Radvanyi (M. D. Anderson Cancer Center, Houston, TX) generously 
donated serum from 14 high dose IL-2 patients receiving treatment at M. D. Anderson 
Cancer Center (Protocol LAB06-0762, P.I. Dr. Laslo Radvanyi).  Rich Joseph in Dr. 
Radvanyi’s laboratory compiled a clinical database of the responses in those patients.   
On this protocol, each cycle of high dose IL-2 therapy consists of 720,000 IU/kg of 
Aldesleukin (human rIL-2) via intravenous infusion over 15 min given up to 12 times per 
cycle, with each dose/infusion spaced 8 h apart.  Cycle 2 is given 21 days later; patients can 
receive up to 12 cycles of therapy depending on tolerance and toxicity.  Patients are assessed 
after cycle 2 by CT and if they progress, they are taken off IL-2 therapy.  Patients with 
disease stabilization or a partial response continue with therapy cycles until no more tumor 
shrinkage occurs, or until they progress or undergo a complete response.  Most people 
withdraw after 2 or more cycles due to toxicity (vascular leak syndrome, fever, fatigue, 
mental confusion, liver dysfunction).  During each cycle, these toxicities are closely 
monitored (especially liver) and if liver dysfunction begins, the infusions are stopped.  Most 
patients can take up to 6-8 infusions per cycle of therapy; some can take all 12.   
Serum was obtained from 10 nonresponders and 4 responders at three separate time 
points – prior to the first dose, 5 hours after the fourth dose, and 2 days after the last dose of 
cycle 1.  Data from our laboratory examining normal serum from 15 donors shows that IL-24 
binds to other serum proteins; markedly higher amounts of IL-24 were detectable by ELISA 
after serum samples were heat released by heating at 56 degrees C for 30 minutes.  Based on 
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this data, patient serum samples were heat released before being analyzed by ELISA for IL-
24 and IL-2 levels. 
Six of 10 nonresponder patients had measurable levels of IL-24 that peaked or 
continued to increase >20% over pretreatment levels after the fourth high dose IL-2 treatment 
time point.  IL-24 levels measured with this assay varied over a wide range from 130 pg/ml 
to 13,700 pg/ml.  The remaining 4 nonresponders as well as all 4 responders had serum levels 
of IL-24 below the limits of our ELISA kit standard curve (<62 picograms/ml) at any of the 
time points tested.  We observed no obvious correlations between quantifiable serum levels 
of IL-24 and any specific responses recorded in the clinical database for this small group of 
patients.  75% of the 4 nonresponders with undetectable IL-24 levels died of their disease 
while the only one third of the 6 nonresponders with measurable IL-24 had died at the time 
these experiments were run.  However, the 4 patients who responded to therapy also did not 
have measurable IL-24 by our assay.  It is possible that any changes in IL-24 level might be 
better detected at an earlier time point.  Furthermore we believe that it is more likely that any 
clinical relationship between measurable differences in IL-24 before and after high dose IL-2 
treatment and patient response to treatment would be better detected in the tumor 
microenvironment and not in the serum. 
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Discussion 
 
IL-2 upregulates IL-24 protein expression leading to growth suppression in melanoma cells 
 In this dissertation, we have shown a novel mechanism of IL-2 action in melanoma 
(Figure 15).  We have established that A375, WM1341, and WM793 melanoma cells have 
IL-24 mRNA while WM35 and MeWo cells lack it.  We have confirmed that high dose IL-2 
has a direct effect on some melanoma cells, causing upregulation of IL-24 protein expression 
and secretion in cell lines that possess IL-24 mRNA.  IL-2 mediates this activity by signaling 
through the IL-2 receptor on these cells; the IL-2Rβ chain in particular appears to be 
essential for this action.  These IL-2 produced increases in IL-24 protein levels subsequently 
result in the suppression of tumor cell growth, and this growth suppression has been 
confirmed to occur in an IL-24 dependent manner.  IL-15, which shares the IL-2Rβ chain 
with IL-2, has also been discovered to be capable of upregulating IL-24 protein expression, 
consequently causing growth suppression in IL-24 positive cells.   
 While we do not disagree with the valuable role of IL-2 as an established 
immunotherapy, these data together give us novel confirmatory evidence that high dose IL-2 
directly affects melanoma tumor cells via its receptor, causing IL-24 upregulation and 
secretion and subsequent tumor growth suppression.  It is possible that the group of patients 
whose melanoma cells respond to IL-2 by producing increased IL-24 are the subset of 
patients with durable responses to high dose IL-2.  We therefore envision exciting 
implications for possible predictive biomarkers of IL-2 response for targeted therapy and 
potential alternative therapeutics for melanoma.  This is promising given our evidence that 
the IL-2Rβ chain plays a significant role in our novel pathway and that only the IL-24 
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positive melanoma cells lines showed growth suppression with high dose IL-2 treatment.  
Additional support for the use of these two molecules as biomarkers of IL-2 response is 
discussed in further detail later in this section.  Of course, we cannot discount the effects of 
high dose IL-2 actions on the immune system.  Although we have shown the direct effects of 
IL-2 on melanoma cells in vitro in the absence of any immune cells and believe that it may 
contribute to patient response to treatment, this mechanism must also be researched in vivo.  
It may be that in the in vivo setting, the effects of IL-2 as an immunotherapy on the immune 
system far outweigh the direct effects seen in vitro.  Therefore, more work must be done to 
determine the direct effects of high dose IL-2 on melanoma cells in vivo. 
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Figure 15. Proposed novel mechanism for IL-2 direct effects on melanoma: IL-24 dependent IL-2 
mediated growth suppression in melanoma cells.  IL-2 binds its receptor (i.e. IL-2Rβ) on melanoma cells 
causing upregulation of IL-24 protein expression (possibly via message stabilization).  These increased levels of 
IL-24 subsequently cause melanoma tumor cell growth suppression both in an autocrine and paracrine 
(bystander) manner in tumor cells with IL-24 receptor. 
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 Upregulation of IL-24 expression has also been reported in the inflammatory 
dermatologic process psoriasis, which involves overactive immune stimulation and excessive 
skin production (psoriatic plaque formation) [127, 128].  Conflicting data has been presented 
in the literature regarding the role of IL-24 in psoriasis.  The pattern of expression of IL-24 
and its receptor in vivo indicate that a major physiological function of IL-24 is its 
involvement in wound healing [59, 129].  Keratinocytes from the epidermis are one of the 
major targets of IL-24 [53, 107].  It is hypothesized that irregularities in IL-24 function may 
contribute to pathological skin conditions such as psoriasis [130].  In psoriasis, IL-24 is 
produced by infiltrating mononuclear cells migrating to the dermal layer directly below the 
psoriatic epidermis [131].  IL-24 protein and receptor overexpression have also been 
observed in the epidermal keratinocytes of psoriatic skin [130, 131], suggesting a potential 
link between the over-activation of IL-24 signaling pathways and overgrowth of 
keratinocytes.  As with other pro-inflammatory cytokines, excess IL-24 can exacerbate 
immunological conditions.  Therefore, constitutive production of IL-24 by the monocytes in 
the dermis in addition to the overexpression of IL-24 and its receptor on keratinocytes could 
lead to continual receptor activation and result in abnormal cell proliferation of the 
keratinocytes in the epidermis; this process would subsequently lead to the development of 
psoriasis.   
 However, it has also been reported by other groups that the expression of three 
specific IL-20/IL-24 combined haplotypes demonstrated a significant protective effect 
against plaque-type psoriasis [132].  One of the IL20/IL24 haplotypes was also associated 
with a reduced risk for palmoplantar pustulosis (pustular psoriasis) [133].  Our laboratory has 
published that IL-24 protein actually inhibits growth factor stimulated proliferation and 
 57
migration of keratinocytes during wound healing, causing the contraction of the wound and 
return of keratinocytes to their normal differentiating processes [134]. Therefore, the loss of 
IL-24 expression, not upregulation, could lead to uncontrolled keratinocyte proliferation and 
abnormal healing.   
 Elevated levels of IL-24 are also seen in patients with latent tuberculosis (TB) [135].  
IL-24 has been determined to modulate IFN-γ expression in patients with tuberculosis 
infection [136].  A correlation exists between IFN-γ expression and the development of TB.  
T cells and NK cells secrete IFN-γ in response to Mycobacterium tuberculosis (Mtb) [137];  a 
defect in IFN-γ would leave the host susceptible to Mtb infection [138]. Therefore, an 
inability to mount a Th1 response may contribute to progression to active tuberculosis.  IL-24 
increases the expression of IFN-γ stimulating cytokines including IL-12, IL-23, and IL-27 in 
PBMC.  Increased IL-24 expression has been reported during viral and bacterial infections 
[139], and IL-24 expression is elevated in newborns that have been BCG vaccinated [140].  
Latent tuberculosis is defined as infection with Mycobacterium tuberculosis, but not active 
tuberculosis disease.  Studies found that patients with latent Mtb infection produce high 
levels of IL-24 and IFN-γ while patients who progress to TB disease have low levels of IL-24 
and IFN-γ [141].  Addition of exogenous IL-24 boosts expression of IFN-γ while 
neutralization of IL-24 results in low expression of IFN-γ.  If the patient progresses to TB 
disease, treatment with exogenous IL-24 may be useful. 
There is significant evidence in the literature substantiating the role of IL-24 as a 
tumor suppressor.  IL-24 has been shown to cause growth suppression and apoptosis in 
numerous different cancer cells including melanoma [124, 125, 142-144].  The Ad.mda-7 
gene construct has been used in Phase I/II gene therapy clinical trials [56, 78, 79, 145] 
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through intratumoral injection of the Ad.mda-7 construct [78, 79].  In the phase I/II clinical 
trials IL-24 was well tolerated and showed considerable apoptotic activity in injected lesions 
[78, 83, 146, 147].  Therefore, overexpression of IL-24 in cancers has a well documented 
anti-tumor effect, and this supports our data that upregulated IL-24 causes melanoma growth 
suppression.   
The idea that IL-2 could have a direct effect on melanoma cells is not unprecedented.  
Other cytokines have also been shown to impose direct effects on a variety of cancer cells.  
The actions of transforming growth factor – beta (TGF-β) in particular have been extensively 
studied in many cancers.  In normal cells TGF-β acts as a tumor suppression regulating a 
wide spectrum of cellular functions including the restriction of cell growth, differentiation, 
and apoptosis [148-150].  Many cancers have been shown to possess the TGF-β receptor.  In 
pancreatic cancer, vascular smooth muscle cancer, and cervical cancers, TGF-β has been 
discovered to induce apoptosis by signaling through its receptor to activate Smad3 signaling 
and repress telomerase reverse transcriptase (TERT) [151].  However, during the 
development of some carcinomas, including colon, breast, and prostate cancer, various 
elements to the TGF-β signaling pathway become mutated.  Research shows that one third of 
colon cancer tumors have mutated TGF-β receptors, and that other tumors have mutations in 
the signaling pathway activated by TGF-β [152-154].  Both of these pro-oncogenic 
conditions lead to unrestricted cell proliferation.  Further studies must been done to 
determine the mechanism and IL-2 signaling pathway elements involved in the direct tumor 
suppressive effects of IL-2 that we have shown in melanoma cells. 
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IL-2 mediates its actions by binding to its receptor [109, 155, 156].  This ligand-
receptor interaction results in activation of Ras/MAPK, JAK/Stat, and PI3-kinase/Akt 
signaling pathways leading to downstream gene transcriptional regulation and the 
proliferation and activation of lymphocytes as shown previously in Figure 2 (151).  
As an immunotherapeutic agent, IL-2 directs its anti-tumor functions through cell-
mediated immunity.  IL-2, formerly called T cell growth factor, drives T cell differentiation 
and proliferation.  It activates T cells and NK cells transforming them into more efficient 
cytotoxic cells called lymphokine activated killer (LAK) cells [157-159].  These LAK cells 
then destroy tumor cells by antibody dependent cell mediated cytotoxicity (ADCC).  They 
bind to the tumor cells directly and secrete cytolysins (perforin and granulysin) which kill the 
target cell.  Early studies of IL-2 as an immunotherapy demonstrated that injection of LAK 
cells and rhIL-2 inhibited the growth of pulmonary metastases and subcutaneous melanoma 
in mice [160]. 
High dose IL-2 received FDA approval for patients with advanced melanoma in 1998 
based on its ability to produce durable responses.  Clinical tumor regression in response to 
high dose IL-2 is well documented in a minority of patients.  Data collected from numerous 
Phase II studies showed a response rate of 16%, with 6% of patients achieving a complete 
response and 10% a partial response [161-164].  One group studied the anti-tumor activity of 
systemic treatment with Salmonella typhimurium expressing IL-2 in a melanoma mouse 
model.  They reported that mice treated with the bacteria showed decreased angiogenesis as 
well as increased tumor necrosis and increased survival times [165].  In humans, a phase II 
trial found that in melanoma patients treated with intralesional IL-2 injections histologic 
studies of patient biopsies showed evidence of tumor necrosis.  Immunofluorescence analysis 
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by confocal laser scanning microscopy revealed caspase 3 staining of tumor cells undergoing 
apoptosis [78, 166, 167].  
Although there have been a few reports of IL-2 receptor and direct IL-2 effects on 
cancer cells, the mechanism of this action is still unclear.  Some groups have reported that 
IL-2 can increase proliferation in some murine and human melanoma cell lines (85-90).  One 
group reported that IL-2 at low doses in the absence of serum appeared to stimulate 
proliferation of some melanoma cell lines but not others during the first 24 hours, while cell 
growth was somewhat suppressed or not seen at higher doses around 500U/ml over the same 
time period [168]. 
IL-2 has been shown to directly inhibit the growth of human squamous cell 
carcinoma of the head and neck (SCCHN) both in vitro and in nude mice bearing SCCHN 
xenografts [169-172].  Growth inhibition in SCCHN cells was completely reversed by 
blocking with an anti-IL-2Rβ antibody and partially reversed by blocking with an anti-IL-
2Rα antibody; this indicates the importance of the intermediate affinity IL-2R for the growth 
suppressive effect of IL-2 in cancer cells (158).   This strongly supports our data that IL-2 
signals through the IL-2Rβ chain and has a direct growth suppressive effect on melanoma 
cells. 
Historically, the general assumption has been that the therapeutic effects of IL-2 are a 
result of its immunomodulatory actions.  However, it is highly likely that the anti-tumor 
effects of high dose IL-2 on cancer cells in responsive patients can be attributed to the direct 
actions of IL-2 on tumors which express the IL-2R in addition to its enhanced immune 
functions.  There is evidence in the literature for the presence of IL-2R on cancer cells and 
IL-2 inhibition of cancer cell growth at high doses.  The literature also confirms the positive 
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effects on disease processes of elevated IL-24, both in its role as a cytokine and as a tumor 
suppressor.  Together with the data we have presented in this dissertation, this evidence 
supports our hypothesis that high dose IL-2 signals through IL-2Rβ directly causing growth 
suppression in some melanoma cells in an IL-24 dependent manner (Figure 15), and that the 
IL-24 and IL-2Rβ status of a tumor may therefore be useful in predicting patient response to 
high dose IL-2 therapy.  Further studies are needed to determine the molecular mechanism 
for IL-2 regulation of IL-24 expression in these cells. 
 
 
Additional support for IL-24 as a potential predictive marker for response to IL-2 therapy 
Although we are aware that IL-24 secreted from melanoma cells may also act as a 
pro-Th1 type cytokine [173] by inducing secondary cytokine production in PBMCs including 
the proinflammatory cytokines IFNγ, IL-1β, IL-12 and TNFα (49), consequently enhancing 
T cell mediated immunity by recruiting tumor infiltrating leukocytes to the site of the tumor, 
this project has focused specifically on the tumor growth suppressive characteristics of IL-24. 
IL-24 has been shown to cause growth suppression and apoptosis in numerous 
different tumor cells including melanoma [144].  Melanoma cells transduced with Ad-mda7 
secrete IL-24 protein which then plays a tumor specific cytotoxic bystander role [70].  Our 
data have now established that high dose IL-2 causes increased IL-24 protein production in 
melanoma cells with IL-24 mRNA; in addition, those same melanoma cells also secrete IL-
24 constitutively and do so at even higher levels following treatment with high dose IL-2.  It 
is possible that the melanoma cells are well acclimated to survival at the concentrations of 
IL-24 they generate endogenously, but that the elevated levels of IL-24 produced in response 
to IL-2 pushes their equilibrium towards growth suppression.  Therefore it is to be expected 
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that this additional secreted IL-24 could also have a paracrine effect by impacting 
neighboring cells within the tumor microenvironment.  It has been reported that the IL-24 
receptor chains are present on melanoma cell lines [174].  Because melanomas are so 
heterogeneous, it may be unlikely that all cells within a tumor will respond directly to IL-2.  
However, even if only a fraction of the cells are capable of responding to IL-2, the remaining 
unresponsive cells which likely possess the IL-24 receptor could be indirectly affected by the 
secreted IL-24 from responding cells.  We propose that given the potential autocrine and 
paracrine bystander tumor growth suppressive effects of elevated IL-24 in high dose IL-2 
patients, IL-24 is an excellent candidate to be a positive predictive marker for response to 
high dose IL-2 therapy. 
Ideally, pretreatment and posttreatment biopsy or fine needle aspirate (FNA) samples 
from high dose IL-2 patients could be examined using immunohistochemistry techniques for 
IL-24 and then follow their clinical response to treatment.  Alternatively, archived tissues 
could be obtained from metastatic melanoma patients through the MD Anderson Melanoma 
Core and perform a retrospective study by examining tissue from responders and 
nonresponders to IL-2 therapy and then correlating IL-24 staining with survival data.  These 
data would substantiate the importance of IL-24 as a predictive marker for responsiveness to 
IL-2 therapy in melanoma patients.  We would expect that patients who respond to high dose 
IL-2 treatment are more likely to express IL-24 in their melanoma tumor cells. 
If showing IL-24 on patient biopsy samples by immunohistochemistry is 
unsuccessful, some alternative approaches for detection of protein on tissue samples include 
qPCR from paraffin embedded tissue, in situ hybridization in tissue, and direct tissue 
proteomics [175].   
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IL-2Rβ or IL-15Rα coexistence with IL-24 as a predictive marker for response to IL-2 
therapy 
Our data demonstrated that stimulating some melanoma cells with IL-2 increases IL-
24 expression via signaling through the IL-2 receptor.  Blocking the IL-2Rβ chain in 
particular had the greatest effect on IL-2 upregulation of IL-24 protein expression.  IL-15, 
which also signals through the IL-2Rβ chain, was likewise able to upregulate IL-24 protein 
expression.  All of these data emphasize the essential role that IL-2Rβ plays in controlling 
IL-24 expression and subsequent tumor growth suppression in these cells.  This observation 
is encouraging because it has been shown that several other cancers, including squamous cell 
carcinoma, renal cell carcinoma, and gastric carcinomas, are growth inhibited by IL-2 
signaling specifically through the IL-2Rβ chain [114, 115].  It happens that the five 
melanoma cell lines tested all contained IL-2Rβ mRNA.  However, this does not imply that 
all melanoma cells will have IL-2Rβ present.  Therefore we propose that the coexistence of 
IL-2Rβ and IL-24 in melanoma cells could potentially be a stronger predictive marker of 
response to IL-2 than IL-24 alone. 
 Other groups have also shown that IL-15Rα is expressed in the melanoma cell lines 
MELP and MELREO [176] as well as in 12 uveal melanoma cell lines [177, 178].  
Secondary cytokines released by IL-2 stimulated lymphocytes include TNFα and IFNγ which 
are known to induce the production of IL-15.  Therefore, IL-15 levels are very likely to be 
elevated in patients receiving high dose IL-2 therapy.  Thus, patients whose melanoma tumor 
cells express IL-15Rα might also respond better to IL-2 therapy by upregulation of IL-24. 
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Support for IL-15 as therapy for metastatic melanoma 
IL-15 is known to be similar to IL-2 in terms of function [179, 180].  Both cytokines 
are capable of facilitating the manufacturing of immunoglobulins produced by B 
lymphocytes and induce the differentiation and proliferation of natural killer (NK) cells 
[180].  The principal differences between IL-2 and IL-15 are associated with the adaptive 
immune response.  IL-2 is involved in maintaining T-Regs and decreases self-reactive T cells 
resulting in a more self tolerant state.  IL-15 is required for maintaining highly specific T cell 
responses by supporting the survival of CD8+ memory T cells [181].  In a recent publication, 
regression of subcutaneous melanoma tumors was seen after intratumoral delivery of an IL-
15 expressing plasmid [182].  Treatment with IL-15 also lacks the secondary cytokine storm 
response seen with IL-2 which causes its capillary leak syndrome side effects [183].  Thus 
dose limiting toxicity of IL-15 is considerably less than that of high dose IL-2.  IL-15 may 
therefore be potentially promising as therapy for melanoma either alone or in combination 
with IL-2 or chemotherapeutics.  In fact, the National Cancer Institute is currently sponsoring 
a Phase I trial exploring the use of recombinant hIL-15 as a treatment for metastatic 
malignant melanoma and metastatic renal cell carcinoma (ClinicalTrials.gov ID: 
NCT01021059, http://clinicaltrials.gov/ct2/show/NCT01021059).  While this study focuses 
on the immunotherapuetic aspect of IL-15, once again, our data show that IL-15 has a direct 
effect on melanoma cells by upregulating expression of IL-24 and causing tumor cell growth 
suppression.  By this reasoning, IL-24 also has the potential to be a promising predictive 
marker for response to IL-15 therapy. 
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Mechanism of IL-2 dependent IL-24 Upregulation in Melanoma Cell Lines 
We have established that in those tumor cells which do respond to IL-2 treatment, IL-
2 mediates this activity by signaling through the IL-2 receptor.  It is important to elucidate 
the mechanism by which this upregulation of IL-24 expression occurs.  We have published in 
vitro data in normal peripheral blood mononuclear cells (PBMC) that show that PHA 
stimulation causes IL-2 secretion which stabilizes IL-24 mRNA resulting in increased protein 
production [84].  It is recognized that the IL-2/IL-2 receptor interaction results in the 
activation of downstream Janus Kinase (Jak)-signal transducer and activator of transcription 
(STAT) pathways which in turn regulate gene transcription.  In T cells, IL-2Rβ signals 
through Jak1 and IL-2Rγ signal through Jak3.  These in turn phosphorylate and activate 
STAT5 and STAT3. 
Since STATs control gene transcription, it is possible that activation by IL-2 causes 
stabilization of IL-24 mRNA message via STAT activation in melanoma cell lines as has 
previously been reported occurs in PBMC [184]; this can be determined by real time RT-
PCR.  To determine whether message stabilization is occurring cells can be treated with IL-2 
followed by Actinomycin D to stop any new RNA transcription.  If there is message 
stabilization, levels of IL-24 mRNA will remain steady when measured over time by real 
time RT-PCR.   
IL-2 induces and regulates the expression of many genes.   As previously discussed, 
IL-2 signals via its receptor through the activation of several different pathways, including 
the JAK/STAT pathway and the p38 MAPK pathway [185-187].  In IL-2 activated Th1 cells, 
IL-2 induces TNFβ production by activating the p38 MAPK pathway (in addition to the 
JAK/STAT pathway) [188].  Another study demonstrated that IL-1β induces p38 MAPK 
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dependent expression of IL-24 in normal human keratinocytes.  The study shows that p38 
MAPK regulates the gene expression of IL-24 in keratinocytes by interfering with IL-24 
mRNA degradation caused by 3’ UTR destabilization [189].  Given these data, another 
possible mechanism for IL-2 regulation of IL-24 expression is by interfering with IL-24 
mRNA degradation via signal transduction through the p38 MAPK pathway. 
Although the three IL-24 positive cell lines we investigated all responded to high 
dose IL-2, it is completely possible that there exist melanoma cells which contain IL-24 
mRNA but are unresponsive to IL-2.  Once we understand the mechanism of IL-2 induction 
of IL-24 in cell lines that do respond we can investigate why the process might not work in 
other cells.  IL-2 unresponsive IL-24 positive cells may lack functional IL-2 receptor chains, 
or could contain mutations or splice variants of downstream elements [178, 190].  To probe 
these possibilities, further downstream events along the IL-2 signaling pathways must be 
examined to determine if differences exist that correlate with melanoma cells’ responsiveness 
to IL-2. 
 
Conclusion 
 Based on the data contained in this dissertation and the available literature reviewed, 
we have presented a novel model for the direct effects of high dose IL-2 on melanoma cells.  
In this model, treatment with high dose IL-2 upregulates IL-24 protein expression which 
leads to melanoma tumor growth suppression.  Currently no reliable marker exists to identify 
and predict the melanoma patients who are most likely to respond positively to IL-2 therapy.  
The results from this study offer insights into several potential predictive biomarkers for 
targeted high dose IL-2 therapy.  Identification of such a marker is essential in order to 
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effectively treat these patients.  IL-2 upregulation of IL-24 may be important for predicting 
clinical response to high dose IL-2 therapy.  Potential markers include the presence of IL-24, 
or coexpression of IL-24 and the IL-2Rβ chain in melanoma cells.  This study also offers 
evidence to support the exploration of IL-15 either alone or in combination with other 
treatments as a potential therapy for melanoma.  We have shown it to be equally capable of 
causing IL-24 dependent melanoma cell growth suppression in comparison with IL-2, and 
the existing literature observes that IL-15 has fewer side effects and toxicity than high dose 
IL-2 therapy. 
Cancers are incredibly complex diseases, and increasing our understanding of the 
molecular mechanisms of both the diseases and the treatments is essential.  Selection of an 
appropriate therapy should be tailored to the individual patient based on his specific tumor 
and immunologic profile.  In fact, the prevailing trend in cancer medicine is toward genetic 
profiling and customized courses of therapy.  It is our hope that this work helps provide a 
predictive marker for IL-2 responsiveness and an identifiable targeted therapy for melanoma. 
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